Sinogliatin is primarily investigated for its potential in treating type 2 diabetes. It functions as a glucokinase activator, which helps regulate blood glucose levels by enhancing insulin secretion and improving glucose metabolism. Clinical trials have shown promise in its ability to lower fasting and postprandial blood sugar levels in diabetic patients. Additionally, it may offer benefits in managing metabolic disorders by improving pancreatic beta-cell function and reducing insulin resistance. Its dual-action mechanism makes it a candidate for combination therapies with other antidiabetic agents. Ongoing research aims to further validate its efficacy and safety in long-term use.